Clark Capital Management Group, Inc. Exelixis, Inc. Transaction History

Clark Capital Management Group, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $1.8 Million - $2.13 Million	89,054 New	89,054 $2.11 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $1.14 Million - $1.32 Million	76,061 Added 98.58%	153,215 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $1.21 Million - $1.72 Million	77,154 New	77,154 $1.21 Million
Q1 2019 May 08, 2019	SELL	$19.6 - $24.76 $5.02 Million - $6.35 Million	-256,307 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $883,837 - $1.41 Million	64,750 Added 33.8%	256,307 $5.04 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $3.04 Million - $4.29 Million	191,557 New	191,557 $3.39 Million

569

249M

1.72M

1.54M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Clark Capital Management Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Clark Capital Management Group, Inc. with notifications on news.